GTx, Inc. (NASDAQ: GTXI) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions. The company’s product candidate in clinical development, ACAPODENE, is a selective estrogen receptor modulator that is in pivotal Phase III clinical trials for the treatment of multiple serious side effects of androgen deprivation therapy for advanced prostate cancer. For further information, visit the Company’s web site at www.gtxinc.com.
- 18 years ago
QualityStocks
GTx, Inc. (NASDAQ: GTXI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…